Setmelanotide: A Novel Targeted Treatment for Monogenic Obesity

Area of Science:

• Pharmacology
• Endocrinology
• Genetics

Background:

• Monogenic obesity results from specific genetic defects affecting appetite regulation.
• Current treatment options for severe genetic obesity are limited.
• Setmelanotide targets the melanocortin 4 receptor (MC4R) pathway, crucial for energy homeostasis.

Purpose of the Study:

• To review clinical data on setmelanotide for chronic weight management.
• To evaluate the efficacy and safety of setmelanotide in monogenic obesity.
• To determine setmelanotide's place in therapy for specific genetic obesity disorders.

Main Methods:

• Literature review of clinical trials (Phase 2 and 3) for setmelanotide.
• Searched MEDLINE, SCOPUS, and EMBASE for relevant studies.
• Included studies evaluating efficacy and safety in adults and children (≥6 years).

Main Results:

• Setmelanotide demonstrated statistically significant weight loss (≥10% body weight) and appetite reduction.
• Common adverse effects: injection site reactions (96%), skin hyperpigmentation (78%), nausea (56%).
• First FDA-approved medication for POMC, PCSK1, and LEPR deficiency-related obesity.

Conclusions:

• Setmelanotide is an effective treatment for obesity linked to specific genetic disorders.
• It offers a targeted therapy for patients with POMC, PCSK1, or LEPR deficiencies.
• Consideration of cost and administration is important for patient access.